Combination therapy for diabetic subjects with insulin and liraglutide
Phase 4
- Conditions
- diabetes mellitus
- Registration Number
- JPRN-UMIN000005565
- Lead Sponsor
- Kanazawa University, Graduate School of Internal Medicine, department of internal medicine
- Brief Summary
BNP and E/E' improved, with BNP levels declining from 36.8+-30.5pg/ml to 26.3+-25.9pg/ml (p=0.0014) and E/E' dropping from 12.7+-4.7 to 11.0+-3.3(p=0.0376). E/E' improved only in patients with E/E' greater than and equal to 13.0. Favorable changes in E/E' were canceled when adjusted for body mass index (BMI). Multivariate linear regression analyses revealed that left ventricular diastolic diameter and deltaE/E'/deltaBMI contributed to deltaBNP/baseline BNP (p=0.0075, R2=0.49264).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
1) endocrine disorders, including type-1 diabetes; 2) refractory malignant tumors; 3) dependency on hemodialysis; and 4) severe hepatic dysfunction (Child-Pugh score greater than equal to 10).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cardiac function on UCG 6 months after the liraglutide introduction
- Secondary Outcome Measures
Name Time Method HbA1c, fasting blood glucose, fasting plasma CPR, urinary CPR, fasting glucagon, T-cho, TG, LDL-C, small dense LDL, pre-beta1HD